NASDAQ:TIL Instil Bio (TIL) Stock Price, News & Analysis $12.53 -0.14 (-1.10%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$12.50▼$12.7050-Day Range$9.70▼$13.5152-Week Range$6.07▼$13.95Volume4,044 shsAverage Volume22,222 shsMarket Capitalization$81.45 millionP/E RatioN/ADividend YieldN/APrice Target$25.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Instil Bio alerts: Email Address Instil Bio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside99.5% Upside$25.00 Price TargetShort InterestHealthy2.10% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($6.91) to ($7.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.83 out of 5 starsMedical Sector438th out of 936 stocksBiological Products, Except Diagnostic Industry65th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingInstil Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInstil Bio has only been the subject of 2 research reports in the past 90 days.Read more about Instil Bio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.10% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Instil Bio has recently increased by 353.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInstil Bio does not currently pay a dividend.Dividend GrowthInstil Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TIL. Previous Next 2.5 News and Social Media Coverage News SentimentInstil Bio has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Instil Bio this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Instil Bio to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Instil Bio insiders have not sold or bought any company stock.Percentage Held by Insiders46.50% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Instil Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Instil Bio are expected to decrease in the coming year, from ($6.91) to ($7.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Instil Bio is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Instil Bio is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInstil Bio has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Instil Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Instil Bio Stock (NASDAQ:TIL)Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Read More TIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TIL Stock News HeadlinesMay 23, 2024 | markets.businessinsider.comPremier Health Reports 2024 Second Quarter ResultsMay 10, 2024 | investorplace.comTIL Stock Earnings: Instil Bio Misses EPS for Q1 2024July 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” May 10, 2024 | markets.businessinsider.comInstil Bio, Inc. Q1 Loss DecreasesMay 10, 2024 | finance.yahoo.comInstil Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | globenewswire.comInstil Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 1, 2024 | finance.yahoo.comBiO-LiFE Herbalmeds Launches The Power of Sleep Campaign To Encourage Malaysians To Sleep Well and Stay HealthyApril 21, 2024 | msn.comThis actor once saw father saved murder accused, qualified for Olympics, then became Bollywood's top villain, died at...July 26, 2024 | Porter & Company (Ad)Obama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” April 17, 2024 | msn.comInstil Bio (TIL) Price Target Decreased by 23.15% to 28.22April 12, 2024 | msn.comJefferies cuts Instil Bio to hold, cites drug discontinuationMarch 22, 2024 | seekingalpha.comInstil Bio Non-GAAP EPS of -$1.26 beats by $2.14March 21, 2024 | globenewswire.comInstil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 12, 2024 | ft.comA Very Private School — Charles Spencer’s privileged but painful educationMarch 11, 2024 | theguardian.comJon Cruddas: ‘Labour has to rediscover its moral purpose’February 24, 2024 | benzinga.comInstil Bio Stock (NASDAQ:TIL) Dividends: History, Yield and DatesFebruary 21, 2024 | sg.yahoo.comAlexei Navalny death latest: Putin brings new criminal case against critic’s brother as mother pleads for bodyFebruary 19, 2024 | msn.comHow RSS textbooks are reshaping Indian history and science under ModiSee More Headlines Receive TIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TIL CUSIPN/A CIK1625584 Webwww.tillcap.com Phone972-499-3350FaxN/AEmployees410Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$32.00 Low Stock Price Target$18.00 Potential Upside/Downside+99.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($18.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-156,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.27% Return on Assets-35.73% Debt Debt-to-Equity Ratio0.40 Current Ratio14.19 Quick Ratio14.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$34.72 per share Price / Book0.36Miscellaneous Outstanding Shares6,500,000Free Float3,480,000Market Cap$81.45 million OptionableNo Data Beta1.17 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Bronson Crouch (Age 51)Chairman & CEO Comp: $672.37kDr. Sandeep Laumas M.D. (Age 55)CFO & Chief Business Officer Comp: $489.14kDr. Mark E. Dudley Ph.D.Chief Scientific OfficerDr. Robert Hawkins MBBSPh.D., Head of Research & DevelopmentKey CompetitorsAtea PharmaceuticalsNASDAQ:AVIRADC TherapeuticsNYSE:ADCTSutro BiopharmaNASDAQ:STROEnanta PharmaceuticalsNASDAQ:ENTAScilexNASDAQ:SCLXView All CompetitorsInstitutional OwnershipAcadian Asset Management LLCSold 3,770 shares on 5/10/2024Ownership: 0.158%View All Institutional Transactions TIL Stock Analysis - Frequently Asked Questions How have TIL shares performed this year? Instil Bio's stock was trading at $7.62 at the beginning of 2024. Since then, TIL shares have increased by 64.4% and is now trading at $12.53. View the best growth stocks for 2024 here. How were Instil Bio's earnings last quarter? Instil Bio, Inc. (NASDAQ:TIL) issued its earnings results on Friday, May, 10th. The company reported ($3.74) EPS for the quarter, missing the consensus estimate of ($2.16) by $1.58. When did Instil Bio's stock split? Shares of Instil Bio reverse split on Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Instil Bio IPO? Instil Bio (TIL) raised $250 million in an initial public offering on Friday, March 19th 2021. The company issued 13,900,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities served as the underwriters for the IPO. How do I buy shares of Instil Bio? Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Instil Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Instil Bio investors own include Bausch Health Companies (BHC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX) and Yamana Gold (AUY). This page (NASDAQ:TIL) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
